Filana Therapeutics (FLNA) closed at $0.62 on October 30, 2026, down 5.5% from the previous close, on volume of 205,917 shares (30-day average 3,964,033).
Data as of October 30, 2026.
30-Oct-2026
Globe Newswire (Wed, 28-Oct 8:00 AM ET)
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Globe Newswire (Fri, 9-Oct 8:00 AM ET)
Market Chameleon (Tue, 22-Sep 5:53 AM ET)
Globe Newswire (Tue, 22-Sep 8:00 AM ET)
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Wed, 12-Aug 2:21 PM ET)
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Filana Therapeutics trades on the NASDAQ stock market under the symbol FLNA.
As of October 30, 2026, FLNA stock price declined to $0.62 with 205,917 million shares trading.
FLNA has a beta of 1.68, meaning it tends to be more sensitive to market movements. FLNA has a correlation of 0.10 to the broad based SPY ETF.
FLNA has a market cap of $30.05 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that FLNA belongs to (by Net Assets): VTI, VXF, VHT, IWC.
FLNA support price is $.63 and resistance is $.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FLNA shares will trade within this expected range on the day.
